Navigation Links
Kindred Biosciences Announces Second Quarter 2014 Financial Results
Date:8/13/2014

our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release.
Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact
Denise Bevers
KindredBio
denise.bevers@kindredbio.com
(650) 701-7909

 

 

 Kindred Biosciences, Inc.Condensed Balance Sheets(In thousands)June 30,
2014December 31,
2013(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

$

9,338$

65,329Short-term investments

103,100Prepaid expenses and other

532148Total current assets

112,97065,477Property and equipment, net

10912Total assets

$

113,079$

65,489LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$

1,711$

689Accrued liabilities

1,6841,521Total liabilities

3,3952,210Stockholders' equity:Common stock

<
'/>"/>
SOURCE Kindred Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
2. Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2014 Financial Results and Provide a Business Update
4. Ambit Biosciences Announces Second Quarter 2014 Operating Results
5. Neurocrine Biosciences Reports Second Quarter 2014 Results
6. Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
7. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
8. Ambit Biosciences To Announce Second Quarter 2014 Financial Results
9. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
10. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
11. Meditope Biosciences Appoints Prominent Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... a pre-clinical study published in the Proceedings ... www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ® ... checkpoint inhibitor), suppression of tumor growth was enhanced ... treating certain hematologic cancers and solid tumors with ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... (DSMB) Authorizes Enrollment of Cervical ... Authorized Dosage Level, HOPKINTON, Mass., Sept. 24 ... independent Data,Safety Monitoring Board (DSMB) has unanimously authorized expanding ... injury (SCI) to,allow subjects with cervical SCI to be ...
... Enrollment Ahead of Schedule with Completion Expected Q2 ... Inc. (Nasdaq: ALTH ) today announced the ... safety data from the,Company,s pivotal Phase 2 PROPEL ... refractory peripheral T-cell lymphoma (PTCL). Results of,the interim ...
Cached Medicine Technology:Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... February 27, 2015 The federal court ... that allege use of the statin medication can increase ... issued a new order pertaining discovery in the cases ... Liebhard LLP comments. The Order, which was issued in ... February 25th, directs the parties to schedule certain witness ...
(Date:2/27/2015)... 27, 2015 Royal River Natural Foods, a ... new study that found adults who got the most magnesium ... diabetes compared to those who got the least magnesium, with ... , The report is part of the March 2015 issue ... River Natural Foods publishes free each month for the Freeport ...
(Date:2/27/2015)... Dr. Andrew Campbell, one of the ... to announce the expansion of Quintessa Aesthetic Center with ... has begun seeing patients on February 18, 2015. , ... offer a variety of state-of-the-art surgical and non-surgical ... laser peels, chemical peels, microdermabrasion, ProFractional Laser, Broad Band ...
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
Breaking Medicine News(10 mins):Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... at Wake Forest University School of Medicine reveals that many ... immediate medical needs of a student or employee who suffers ... to support a new statewide program to place automated external ... to appear in the May/June 2009 issue of the ...
... (SIS) unveils SIS Trax, a tissue management solution that ... for hospitals to standardize their processes for acquiring, receiving, ... solution to be fully integrated with a perioperative information ... enables hospitals to improve patient safety, optimize revenue, reduce ...
... Conference Vice President for Public Policy Paul A. ... executive order to be issued by President Obama ... cell research:"President Obama,s executive order regrettably places ideology ... advancements. There are endless studies and stories ...
... Connectivity to be Presented at HIMSS09LOS ANGELES, ... (OTC Bulletin Board: FVRL), which through its ... provides Web-based consumer-controlled Personal Health Records ("PHRs") ... box storage solutions ( www.myesafedepositbox.com ), announced ...
... Chef Cat Cora ( www.catcoracooks.com ), ... Chef of Bon Appetit is excited to announce she ... her first pregnancy and the fourth child for the Cora family. ... deliver their third child, also a boy, in April. "Jennifer and ...
... Seen in Patient Delays and Unnecessary StaysCOLLEGE PARK, Md., March ... Maryland,s Robert H. Smith School of Business put a ... hospitals at $12 billion per year. The research, newly released ... is the first to quantify the economic impact of a ...
Cached Medicine News:Health News:Study prompts new mandate for N.C. high schools 2Health News:Study prompts new mandate for N.C. high schools 3Health News:SIS Trax Unveiled as First Fully Integrated Tissue Management Solution 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 2Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 3Health News:MyMedicalRecords Adds Enhanced Doctor-Patient Features to Its Flagship Personal Health Record Platform 4Health News:Celebrity Chef Cat Cora Announces First Pregnancy 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 2Health News:U.S. Hospitals Waste $12 Billion Annually Because of Poor Communication 3
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 7mm from end. Two .15mm ports 2mm, ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 21G x 7/8in (.80 ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
For injecting anesthetics into the muscle cone. 25G x 1 1/2 in (.50 x 38mm)...
Medicine Products: